Aquestive Therapeutics, Inc. Research and Development Expense
Aquestive Therapeutics, Inc. (AQST) reported Research and Development Expense of $3.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Aquestive Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $3.96M, a 3.48% decline year-over-year.
- Aquestive Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $4.20M, a 21.58% decline year-over-year.
- Aquestive Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $3.20M, a 35.00% decline year-over-year.
- Aquestive Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $4.53M, a 14.03% decline year-over-year.
- Aquestive Therapeutics, Inc. research and development expense for fiscal 2025 was $17.19M, a 15.23% decline from fiscal 2024.
- Aquestive Therapeutics, Inc. research and development expense for fiscal 2024 was $20.28M, a 54.76% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. research and development expense for fiscal 2023 was $13.10M, a 25.04% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. research and development expense for fiscal 2022 was $17.48M, a 2.55% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.96M 10-Q · filed 2026-08-11 | $8.17M 10-Q · filed 2026-08-11 | $11.36M derived: sum of 3 quarters · filed 2026-08-11 | $15.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-13 | $7.40M derived: sum of 2 quarters · filed 2026-05-13 | $11.93M derived: sum of 3 quarters · filed 2026-05-13 | $16.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $7.73M derived: sum of 2 quarters · filed 2026-03-04 | $11.83M derived: sum of 3 quarters · filed 2026-08-11 | $17.19M 10-K · filed 2026-03-04 |
| 2025-09-30 | $4.53M 10-Q · filed 2025-11-05 | $8.63M derived: sum of 2 quarters · filed 2026-08-11 | $14.00M 10-Q · filed 2025-11-05 | $18.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.11M 10-Q · filed 2026-08-11 | $9.47M 10-Q · filed 2026-08-11 | $14.38M derived: sum of 3 quarters · filed 2026-08-11 | $19.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.36M 10-Q · filed 2026-05-13 | $10.28M derived: sum of 2 quarters · filed 2026-05-13 | $15.55M derived: sum of 3 quarters · filed 2026-05-13 | $19.71M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $10.19M derived: sum of 2 quarters · filed 2026-03-04 | $14.35M derived: sum of 3 quarters · filed 2026-03-04 | $20.28M 10-K · filed 2026-03-04 |
| 2024-09-30 | $5.27M 10-Q · filed 2025-11-05 | $9.43M derived: sum of 2 quarters · filed 2025-11-05 | $15.36M 10-Q · filed 2025-11-05 | $18.25M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.16M 10-Q · filed 2025-08-11 | $10.09M 10-Q · filed 2025-08-11 | $12.98M derived: sum of 3 quarters · filed 2025-08-11 | $16.18M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $5.93M 10-Q · filed 2025-05-12 | $8.82M derived: sum of 2 quarters · filed 2025-05-12 | $12.02M derived: sum of 3 quarters · filed 2025-05-12 | $15.49M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $6.08M derived: sum of 2 quarters · filed 2025-03-05 | $9.56M derived: sum of 3 quarters · filed 2025-03-05 | $13.10M 10-K · filed 2025-03-05 |
| 2023-09-30 | $3.20M 10-Q · filed 2024-11-04 | $6.67M derived: sum of 2 quarters · filed 2024-11-04 | $10.22M 10-Q · filed 2024-11-04 | $14.49M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $3.47M 10-Q · filed 2024-08-06 | $7.02M 10-Q · filed 2024-08-06 | $11.30M derived: sum of 3 quarters · filed 2024-08-06 | $14.53M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $3.55M 10-Q · filed 2024-05-07 | $7.83M derived: sum of 2 quarters · filed 2024-05-07 | $11.06M derived: sum of 3 quarters · filed 2024-05-07 | $16.25M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $7.51M derived: sum of 2 quarters · filed 2024-03-05 | $12.71M derived: sum of 3 quarters · filed 2024-03-05 | $17.48M 10-K · filed 2024-03-05 |
| 2022-09-30 | $3.23M 10-Q · filed 2023-11-06 | $8.43M derived: sum of 2 quarters · filed 2023-11-06 | $13.20M 10-Q · filed 2023-11-06 | $17.60M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $5.20M 10-Q · filed 2023-08-07 | $9.97M 10-Q · filed 2023-08-07 | $14.37M derived: sum of 3 quarters · filed 2023-08-07 | $19.10M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $4.77M 10-Q · filed 2023-05-02 | $9.17M derived: sum of 2 quarters · filed 2023-05-02 | $13.90M derived: sum of 3 quarters · filed 2023-05-02 | $18.16M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $9.13M derived: sum of 2 quarters · filed 2023-03-31 | $13.39M derived: sum of 3 quarters · filed 2023-03-31 | $17.05M 10-K · filed 2023-03-31 |
| 2021-09-30 | $4.73M 10-Q · filed 2022-11-01 | $8.99M derived: sum of 2 quarters · filed 2022-11-01 | $12.65M 10-Q · filed 2022-11-01 | $17.07M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $4.26M 10-Q · filed 2022-08-02 | $7.92M 10-Q · filed 2022-08-02 | $12.35M derived: sum of 3 quarters · filed 2022-08-02 | $19.61M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $3.66M 10-Q · filed 2022-05-04 | $8.08M derived: sum of 2 quarters · filed 2022-05-04 | $15.34M derived: sum of 3 quarters · filed 2022-05-04 | $19.19M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $11.69M derived: sum of 2 quarters · filed 2022-03-08 | $15.53M derived: sum of 3 quarters · filed 2022-03-08 | $19.89M 10-K · filed 2022-03-08 |
| 2020-09-30 | $7.26M 10-Q · filed 2021-11-02 | $11.11M derived: sum of 2 quarters · filed 2021-11-02 | $15.46M 10-Q · filed 2021-11-02 | $18.52M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $3.85M 10-Q · filed 2021-08-03 | $8.20M 10-Q · filed 2021-08-03 | $11.26M derived: sum of 3 quarters · filed 2021-08-03 | $16.32M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $4.35M 10-Q · filed 2021-05-04 | $7.41M derived: sum of 2 quarters · filed 2021-05-04 | $12.47M derived: sum of 3 quarters · filed 2021-05-04 | $20.63M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $8.12M derived: sum of 2 quarters · filed 2021-03-09 | $16.27M derived: sum of 3 quarters · filed 2021-03-09 | $20.57M 10-K · filed 2021-03-09 |
| 2019-09-30 | $5.06M 10-Q · filed 2020-11-04 | $13.21M derived: sum of 2 quarters · filed 2020-11-04 | $17.52M 10-Q · filed 2020-11-04 | $23.20M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $8.15M 10-Q · filed 2020-08-04 | $12.45M 10-Q · filed 2020-08-04 | $18.14M derived: sum of 3 quarters · filed 2020-08-04 | $22.67M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | $4.30M 10-Q · filed 2020-05-05 | $9.99M derived: sum of 2 quarters · filed 2020-05-05 | $14.52M derived: sum of 3 quarters · filed 2020-05-05 | $22.51M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | $5.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $10.22M derived: sum of 2 quarters · filed 2020-03-11 | $18.21M derived: sum of 3 quarters · filed 2020-03-11 | $23.11M 10-K · filed 2020-03-11 |
| 2018-09-30 | $4.53M 10-Q · filed 2019-11-05 | $12.53M derived: sum of 2 quarters · filed 2019-11-05 | $17.43M 10-Q · filed 2019-11-05 | $23.70M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $7.99M 10-Q · filed 2019-08-06 | $12.89M 10-Q · filed 2019-08-06 | $19.17M derived: sum of 3 quarters · filed 2019-08-06 | $24.85M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $4.90M 10-Q · filed 2019-05-08 | $11.17M derived: sum of 2 quarters · filed 2019-05-08 | $16.86M derived: sum of 3 quarters · filed 2019-05-08 | $21.69M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $11.96M derived: sum of 2 quarters · filed 2019-03-14 | $16.79M derived: sum of 3 quarters · filed 2019-03-14 | $22.13M 10-K · filed 2019-03-14 |
| 2017-09-30 | $5.68M 10-Q · filed 2018-11-06 | $10.52M derived: sum of 2 quarters · filed 2018-11-06 | $15.86M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $4.84M 10-Q · filed 2018-09-04 | $10.18M 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |